Study of two drugs for untreated follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two medications (obinutuzumab and CC-99282) for people with a type of lymphoma called follicular lymphoma that has not been treated before and is considered high-burden (meaning it is widespread or growing quickly). The goal is to see if this combination helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have follicular lymphoma that has not been treated yet.
- Your lymphoma is advanced (Stage II, III, or IV) or has a high tumor burden.
- You are at least 18 years old.
- You are willing to use effective contraception if you or your partner could become pregnant.
- You have not had major surgery recently, and you do not have certain heart, bleeding, or immune system conditions.
- You have not had prior treatment with certain targeted therapies (like CD20 antibodies or immunomodulators).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This real-world study looks at how well obinutuzumab-based treatment works for people with newly diagnosed follicular lymphoma. It is meant for patients whose cancer is measurable on scans and who are eligible for specific standard treatment combinations.
This study tests whether adding obinutuzumab (an antibody medicine) to local radiation works better than radiation alone in early-stage follicular lymphoma. It aims to improve disease control while keeping treatment safe.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
This trial tests a combination of two targeted drugs, zanubrutinib and obinutuzumab, for people who have just been diagnosed with follicular lymphoma. The goal is to see if this combination works well and is safe.
This study looks at giving obinutuzumab together with lenalidomide to adults whose follicular lymphoma has come back or did not respond well to prior treatment. It may help control the cancer after relapse or resistance to standard therapies.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.